Bajaj Healthcare Limited
Established in the year 1993, Bajaj Healthcare Ltd is an estalished player in the Indian Pharmacuetical Industry and fastest growing mid-cap pharmaceutical companies in India.
What Bajaj files
- Others73
- Important20
- Updates17
- Board Meeting11
- Investor Meet7
- Dividend/Bonus4
Bajaj Healthcare granted 275 employee stock options, each convertible into one equity share, at an exercise price of Rs. 5. This move incentivizes key personnel and results in minimal potential share dilution for investors.
Bajaj Healthcare received initial approval from the CDSCO's Subject Expert Committee to manufacture and market Cenobamate Tablets (a next-gen antiseizure medication). This makes BHL the first Indian company to secure this clearance, reinforcing its specialty pharma position.
Bajaj Healthcare reports Q3 revenue of ₹161.22 Cr, PAT ₹15.67 Cr. Nine-month revenue hit ₹457.97 Cr, PAT ₹38.62 Cr. Board approved re-appointing key directors for three-year terms. Acquisition of Genrx Pharma for ₹10.85 Cr is pending NCLT approval.
Bajaj Healthcare granted 58,900 employee stock options at an exercise price of Rs 5 each under its ESOP 2024 plan. This move aims to incentivize employees and aligns their interests with long-term company growth, with potential future equity dilution.
Bajaj Healthcare's Board has approved Q1 financial results. Revenue from operations for the quarter stood at ₹148.84 Cr, with a Profit after Tax from continuing operations of ₹12.17 Cr. The company recently completed a preferential issue, raising ₹152.26 Cr, primarily used for loan repayment. An additional ₹52.71 Cr from warrants...